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Abstract 
Background and purpose:  Rheumatic valvular heart disease is associated with increased 
risk of cerebrovascular events, although there are limited data on the prognosis of patients 
with rheumatic mitral valve disease (RMVD) following stroke.   
Methods:  We examined the association between RMVD and both serious and common 
cardiovascular and non-cardiovascular (respiratory and infective) complications in a cohort of 
hospitalised stroke patients based in Thailand. Factors associated with in-hospital mortality 
were also explored. Data were obtained from a National Insurance Database. All hospitalised  
strokes between 1st October 2004 and 31st January 2013 were included in the current study. 
Characteristics and outcomes were compared for RMVD and non-RMVD patients. Logistic 
regression, propensity score matching, and multivariate models were employed to assess 
study outcomes. 
Results: In total, 594,681 patients (mean (SD) age=64(14.5) years) with a diagnosis of stroke 
(ischemic = 306,154; hemorrhagic= 195,392; undetermined = 93,135) were included in this 
study, of whom 5461 had RMVD. Results from primary analyses showed that following 
ischemic stroke, and controlling for potential confounding covariates, RMVD was associated 
(P<0.001) with increased odds for cardiac arrest (OR(95%CI)=2.13(1.68-2.70)), shock 
(2.13(1.64-2.77)), arrhythmias (1.70(1.21-2.39)), respiratory failure (2.09(1.87-2.33)), 
pneumonia (2.00(1.81-2.20)), and sepsis (1.39(1.19-1.63)). In hemorrhagic stroke patients, 
RMVD was associated with increased odds (fully adjusted model) for respiratory failure 
(1.26(1.01-1.57)), and in patients with undetermined stroke, RMVD was associated with 
increased odds (fully adjusted analyses) for shock (3.00(1.46-6.14)), respiratory failure 
(2.70(1.91-3.79)), and pneumonia (2.42(1.88-3.11)).  
Conclusions:  RMVD is associated with development of cardiac arrest, shock, arrhythmias, 
respiratory failure, pneumonia, and sepsis following acute stroke. 
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Introduction 
Rheumatic valvular heart disease is the most common form of acquired heart disease 
in children and young adults in many parts of the world. In a 2005 summary report 
commissioned by the World Health Organisation, the overall global burden of this disease 
was estimated to be 15.6 million prevalent cases with 282,000 new cases and 233,000 deaths 
per year1. These extrapolated figures are based on limited data and likely underestimate the 
true burden of this condition in endemic regions such as sub-Saharan Africa, south-central 
Asia, the Pacific, and indigenous populations of Australia and New Zealand2-4. The 
populations in these areas are also likely to have significant exposure to risk factors for 
cerebrovascular disease such as smoking, regular use of alcohol, and poor nutrition, as well 
higher prevalence of hypertension, hypercholesterolemia and diabetes5-7. This may explain 
why many of these regions also have high incidence and mortality rates for stroke8.  
Mitral valve disease is the most prevalent early valvular manifestation of rheumatic 
heart disease. Associated left atrial dilation increases the likelihood for development of atrial 
fibrillation, with stasis of blood flow elevating the risk for arterial thromboembolism9. By 
virtue of their common underlying socioeconomic risk factors, rheumatic mitral valve disease 
(RMVD) and stroke are inextricably linked in many developing countries worldwide. 
Nevertheless, there are currently limited data on prognostic implications of RMVD following 
stroke, although advancing age, female gender, and history of cerebrovascular events, chronic 
ischemic heart disease, and congestive heart failure have previously been identified as 
independent predictors of death in RMVD patients10-13.  
We aimed to examine the effect of RMVD on a comprehensive range of serious and 
common cardiovascular and non-cardiovascular (respiratory and infective) complications in a 
large cohort of hospitalised stroke patients. We also aimed to explore factors associated with 
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in-hospital mortality in this cohort whilst controlling for patient characteristics, history of 
comorbid conditions, and post stroke complications. 
 
Methods 
Study participants and design 
So as to optimally address our research objective, we employed an observational 
epidemiological approach using routine consecutive admission data representative of all 
hospital admissions. This approach overcomes selection bias which is the major limitation of 
clinical studies including trials. Study participants comprised a prospectively identified 
cohort of 594,681 participants (mean (SD) age = 64 (14.5) years) admitted to provincial and 
large community hospitals in Thailand between 1st October 2004 and 31st January 2013 who 
received a diagnosis of stroke. We selected this time period as stroke management in 
Thailand has become more in line with current international practice since 2004. Data were 
obtained from the Universal Coverage Health Security Insurance Scheme Database in 
Thailand. The Thai population is covered by three insurance schemes. The Civil Servant 
Benefit System covers government employees and their dependants (~7% of the population), 
and the Social Security scheme covers private sector employees (~13% of the population). 
The Universal Coverage Health Security Scheme is a basic health insurance scheme covering 
the remainder of the population14. 
In Thailand, diagnosis of stroke is made during individuals’ inpatient hospital stay by 
attending clinical teams based on clinical features and investigation findings including brain 
imaging (since 2009 all patients with suspected stroke received a head CT scan). All 
hospitalised patients were clinically managed in accordance with Thai National Clinical 
Practice Guidelines. This includes ECG monitoring for at least 24-hours following hospital 
admission. Demographic and clinical data were obtained from insurance reimbursement 
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forms using International Classification of Disease (ICD-10) codes on an annual basis. Stroke 
types were categorised as hemorrhagic (I61, I62), ischemic (I63) or stroke of undetermined 
pathology (I64). Diagnoses of RMVD and other comorbid conditions were identified from 
ICD coding (ICD-10) on reimbursement forms (stroke (I61-I64), RMVD (I05), hypertension 
(I10), ischaemic heart disease (I25), atrial fibrillation and flutter (I48), heart failure (I50), 
anaemia (D50,D53,D56,D58,D59), type II diabetes mellitus (E11), dyslipidaemia (E78), 
chronic kidney disease (N18), and HIV (Z21)). Our study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the Ethics 
Committee in Human Research, Khon Kaen University, Khon Kaen, Thailand. 
 
Outcome measures 
Serious and common cardiovascular and non-cardiovascular post-stroke 
complications were examined as primary outcomes in this study.  In hospital mortality 
following stroke was also examined.  Data were collected for each patient on age, gender, and 
previous history of major chronic disease (stroke, heart failure, primary hypertension, 
dyslipidaemia, atrial fibrillation and flutter, chronic kidney disease, COPD, chronic ischemic 
heart disease, type II diabetes mellitus, and HIV). Data on post stroke cardiovascular 
complications (cardiac arrest, myocardial infarction, shock, and arrhythmias), respiratory 
failure, and infective complications (pneumonia, and sepsis) were recorded also, as were 
length of hospital stay and mortality status at discharge.   
 
Statistical methods 
Analyses were performed using SPSS for Windows version 23.0 (SPSS Inc., Chicago, 
IL, USA) for descriptive statistics and regression models and Stata version 14 (StatCorp, 
USA) for propensity score matched models. Descriptive statistics were calculated separately 
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for study participants with and without RMVD. Continuous variables were presented as mean 
values (± SD), and for categorical variables the number and percentage were given. 
Characteristic data and stroke outcomes were compared between patients with and without 
RMVD using independent samples t-tests for continuous variables and chi-squared tests for 
categorical variables.  
The effect of RMVD on the development of complications following stroke (cardiac 
arrest, acute myocardial infarction, shock, arrhythmias, respiratory failure, infective 
endocarditis, pneumonia, and sepsis) was examined using logistic regression for each stroke 
subtype (ischemic, haemorrhagic, or undetermined). The reference category for these 
regression models was ‘patients with no RMVD’, and patient complications were the 
dependent variables.  
For all complications we examined unadjusted outcomes (model A), and outcomes 
adjusted for age, gender, and previous history of major chronic disease (stroke, heart failure, 
chronic kidney disease, COPD, cancer, chronic ischemic heart disease, diabetes, and HIV) 
(model B). For cardiovascular complications (cardiac arrest, acute myocardial infarction, 
shock, arrhythmias), the influence of additional covariates relevant to cardiovascular function 
in hospitalised patients were examined by submitting them in isolation to model B. 
Adjustment was made for presence of existing primary hypertension, dyslipidaemia, and 
atrial fibrillation and flutter (models C, D, and E respectively). For the complication of 
respiratory failure, additional adjustment was made for presence of post stroke pneumonia 
which can be closely linked to respiratory failure in the critically ill (model C). 
The association of rheumatic mitral valve disease with complications following stroke 
was further examined using propensity score matching analysis. This approach matches 
RMVD patients with unaffected patients that are comparable for all observed covariates, 
thereby minimising bias due to confounding. Propensity scoring was carried out using full 
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Mahalanobis matching in Stata using the psmatch2 command, using logistic regression to 
estimate the propensity scores. Matching was then carried out on a 1:1 basis. The explanatory 
factors in the matching were age, gender, and previous history of major chronic disease 
(stroke, heart failure, chronic kidney disease, COPD, cancer, chronic ischemic heart disease, 
diabetes, and HIV). 
Factors associated with in-hospital mortality following stroke were examined using 
multivariate logistic regression analysis with in-hospital mortality as the dependent variable. 
Covariates were entered using forward selection with a cut-off of 10% significance level 
from patient demographic and pre-existing comorbidity data (model A). A further 
multivariate model (B; generated as described above) examined additional adjustment for the 
post-stroke complications. 
 
Results 
From 594,681 study participants with diagnosis of stroke (ischemic = 306,154; 
hemorrhagic= 195,392; undetermined subtype = 93,135), 5461 had pre-existing RMVD. 
Table 1 shows sample characteristics for participants with and without RMVD. Participants 
with RMVD were significantly younger, more likely to be female, and had lower prevalence 
of pre-existing hypertension, dyslipidaemia, and type II diabetes (P<0.001). The proportion 
of participants with pre-existing heart failure, atrial fibrillation and flutter, ischemic heart 
disease, and anaemia was significantly higher in those with RMVD, as was the incidence of 
ischemic stroke (whereas incidence of hemorrhagic and undetermined stroke subtypes were 
lower) (P<0.001). 
Table 2 shows the proportion of study participants suffering serious post stroke 
complications (stratified by presence or absence of RMVD). Rate of in-hospital mortality was 
lower in participants with RMVD (10.4% vs. 11.8%; P<0.001). Participants with RMVD had 
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higher incidences of respiratory failure, pneumonia, sepsis, acute myocardial infarction, 
arrhythmias, cardiac arrest, and shock (when compared with those without RMVD; P<0.001). 
Median (IQR) length of hospital stay was longer in participants with RMVD than those 
without (4(5) vs. 3(4) days respectively; P<0.001).     
 Table 3 shows odds ratios and corresponding 95% CIs from binary logistic regression 
analyses examining the association of RMVD with serious complications following stroke 
(where no mitral valve disease was the reference category). For patients diagnosed with 
ischemic stroke, and when controlling for age, gender, and previous history of major chronic 
disease (stroke, heart failure, chronic kidney disease, COPD, chronic ischemic heart disease, 
type II diabetes, and HIV) (model B), presence of RMVD was associated (P<0.003) with 
increased odds for developing cardiac arrest, shock, arrhythmias, respiratory failure, 
pneumonia, and sepsis. Associations remained significant (with the exception of arrhythmias) 
following additional covariate adjustment (primary hypertension, dyslipidaemia, and atrial 
fibrillation and flutter for cardiovascular complications (models C-E respectively); and post-
stroke pneumonia for respiratory failure (model C)).  
For hemorrhagic stroke, presence of RMVD was associated with increased odds for 
respiratory failure (Model C OR (95% CI) = 1.26 (1.01-1.57) P=0.04). For undetermined 
stroke subtype, presence of RMVD was associated with increased odds (P<0.001) for post-
stroke shock (OR = 3.00 (1.46-6.14)), respiratory failure (OR = 2.70 (1.91-3.79)), and 
pneumonia (OR = 2.42 (1.88-3.11)) (model B). These associations remained significant 
following additional covariate adjustment (primary hypertension, dyslipidaemia, and atrial 
fibrillation and flutter for shock (models C-E); and post-stroke pneumonia for respiratory 
failure (model C)).  
 Propensity score matched results (supplementary Table I; please see 
http://stroke.ahajournals.org) were comparable with those from logistic regression analyses. 
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In patients diagnosed with ischaemic stroke, presence of RMVD was associated with 
increased odds for developing cardiac arrest, shock, respiratory failure, pneumonia, and 
sepsis (P<0.002). Following haemorrhagic stroke, RMVD was associated with increased 
odds for respiratory failure (OR=2.48(1.72-3.58)), and sepsis (OR=2.55(1.39-4.69)). In 
patients with undetermined stroke subtype, presence of RMVD was associated with increased 
odds for respiratory failure (OR=5.50(2.43-12.40)) and pneumonia (OR=3.03(1.64-5.61)). 
Multivariate analysis showed that factors associated (P<0.001) with in-hospital 
mortality following ischemic stroke were increasing age, female gender, history of stroke, 
heart failure, chronic kidney disease, chronic ischemic heart disease, HIV, and development 
of post-stroke myocardial infarction, shock, arrhythmias, respiratory failure, pneumonia, and 
sepsis (Supplementary Table II; please see http://stroke.ahajournals.org). Associations were 
consistent across stroke subtype. Similar findings were seen for hemorrhagic stroke although 
female gender was not associated with in hospital mortality in this group. For undetermined 
stroke subtype, type II diabetes was additionally associated with in hospital mortality whereas 
history of previous stroke was not.       
 
Discussion 
We present the largest population-based study to investigate prognosis after stroke in 
patients with RMVD. Strengths of our analyses include prospective identification of study 
participants, and a representative study population drawn from the community. We used 
specific ICD codes for ischemic and hemorrhagic stroke rather than the broader and more 
general ICD codes (I60-69) used in other population based studies. This allowed a more 
detailed sub-analysis of prognosis based on underlying stroke type. In addition, by validating 
population-based insurance data of all participants with hospital admission data, we have 
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been able to take detailed co-morbidity information into account during analyses in a way 
that has not previously been possible in this setting. 
The group of stroke patients with RMVD were substantially younger and largely 
female (70.1%), similar to previous studies of rheumatic heart disease patients15-17. 
Participants without RMVD were more likely to suffer from hypertension, dyslipidaemia, and 
type II diabetes mellitus. This is consistent with the morbidity profile of older individuals 
from Asia18. Lower rate of in-hospital mortality for patients with RMVD compared with non 
RMVD patients may be explained by differences in age and comorbid characteristics given 
the increased odds for in hospital mortality with RMVD following robust covariate 
adjustment.   
RMVD patients were significantly more likely (compared to patients without RMVD) 
to present with a diagnosis of ischemic stroke. These patients had more cardiovascular co-
morbidities such as heart failure, atrial fibrillation and flutter, ischemic heart disease, and 
anaemia. It is unclear what proportion of this association with ischemic stroke is due to the 
pathophysiology of RMVD and what proportion is due to shared underlying socioeconomic / 
cardiovascular risk factors such as poor diet, smoking, and excessive alcohol consumption in 
the lower socio-economic regions where RMVD is more common2-4.  
When comparing stroke patients with RMVD to those without RMVD, a number of 
complications (respiratory failure, pneumonia, sepsis, acute myocardial infarction, 
arrhythmias, cardiac arrest, shock) were more common in the presence of RMVD. In order to 
better understand potential mediators of these associations, further adjustments were made to 
our models by including additional covariates relevant to respiratory and cardiovascular 
function in isolation. Associations remained consistent for complication outcomes across all 
stroke subtypes with the exception of RMVD associated arrhythmias in ischemic stroke 
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patients following adjustment for atrial fibrillation and flutter. This may relate to over 
adjustment bias. 
In adjusted analyses RMVD patients had significantly greater odds for in-hospital 
mortality compared to those without. This could be linked to reduced cardiovascular reserve 
to compensate for the physiological stress following stroke in the presence of RMVD. When 
assessing factors associated with mortality in stroke patients, the clinical impact of pre-
existing comorbid conditions on mortality risk becomes apparent. Increased mortality risk in 
the presence of comorbidities likely relates to a myriad of pathological processes (such as 
dyslipidaemia, chronic inflammation, endothelial dysfunction, hypertension, volume 
overload, impaired left ventricular function, microvascular disease, and immune 
compromise)19-22.  
Whereas age-adjusted stroke incidence rates in high-income countries have decreased 
by 42% since the 1970s, the stroke incidence rates in low to middle income countries have 
more than doubled during this period (52 per 100 000 and 117 per 100 000 person-years, 
respectively; p<0.0001) with little sign of slowing23. As a result, the incidence of stroke in 
low- to middle-income countries has now exceeded that of high-income countries. 
Furthermore, these low- to middle-income countries often have younger stroke sufferers and 
higher stroke-related mortality24-25.  
The prevalence of rheumatic valvular heart disease, which is highest in children in 
resource poor nations26, is likely to be underestimated in these regions due to reliance on 
clinical screening criteria that lack the sensitivity to detect all cases of the condition15. 
Rheumatic fever following group A streptococcus infection is the predominant cause for 
rheumatic valvular heart disease. Progressive damage to the heart and its valves is associated 
with clinical complications such as asymptomatic irreversible ventricular dysfunction, 
pulmonary hypertension, atrial fibrillation and flutter, and stroke, which are major causes of 
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long-term morbidity27. In terms of global public health, if we are to limit the burden of these 
adverse outcomes, preventative strategies should focus on improving diagnosis and 
management of rheumatic fever and resultant valvular heart disease. Emphasis should be 
placed on reinforcing current control strategies such as recognition and treatment of 
streptococcal pharyngitis for primary prevention of rheumatic fever and long-term 
antistreptococcal prophylaxis for secondary prevention 27, and improving general living 
conditions. 
We acknowledge some limitations. We did not have information on the severity of 
mitral value disease or the clinical severity of the stroke, nor did we have information on 
medication use and therefore cannot account for potential effects of pre stroke cardiovascular 
medication (e.g. antihypertensive use) on stroke severity. Furthermore, no information was 
available around left ventricular function in patients with or without RMVD that may have 
confounded some of the relationships that we have reported. It was not possible to examine 
data from patients who suffered mild strokes not admitted to hospital or very severe strokes 
resulting in death prior to admission. Nevertheless, truncation of distribution would be likely 
to attenuate the associations.  
Despite robust adjustment for a wide range of pre-existing comorbidities, our 
outcomes may be limited by residual confounding. It is possible that worse prognosis 
following stroke in RMVD patients could be attributable to other factors that were not 
adjusted for in our analyses such as biological covariables which were unavailable. Inclusion 
of these data however is likely more relevant for examination of outcomes over the longer 
term such as incident cardiovascular disease and stroke recurrence28-29. Our propensity score 
matched results were markedly similar to those obtained from logistic regression. 
Consistency of outcome data further reduces the likelihood that outcomes may be related to 
unmeasured confounding covariates. 
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Participant data were collected during acute hospital admission and we therefore have 
limited follow up information. Mortality from stroke however is particularly prominent in the 
short term (0-30 days post event)30, and thus examination of short-term outcomes has the 
potential to significantly affect overall stroke mortality. We were unable to comprehensively 
control for socioeconomic factors that may underlie RMVD such as habitual diet, smoking, 
and excessive alcohol consumption. However, the main focus of the current work is to 
quantify the prognostic impact of RMVD on stroke outcome. 
Conclusions 
We have conducted the largest study to date that reports on the impact of valvular 
heart disease on complications following stroke. Certain concomitant comorbidities and post-
stroke complications are more common in RMVD stroke patients. These patients are at 
greater risk for in-hospital mortality, and their prognosis is significantly worsened by the 
presence of a number of post-stroke complications which presents unique challenges for 
patient management. The worldwide prevalence of RMVD is increasing and will continue to 
rise in western countries given the likely future trends in valvular heart disease 
epidemiology31. There is an urgent need for further work on how to better understand and 
manage potentially reversible causes of morbidity and mortality in these patients. 
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Table 1:  Patient characteristics 
Characteristic Mitral valve disease  No mitral valve disease P* 
N 5461  589220  
Age†, years  55 (13.9) 64 (14.5) <0.001 
Gender 
Male 
Female 
 
1632 (29.9) 
3829 (70.1) 
 
325535 (55.2) 
263685 (44.8) 
 
 
<0.001 
Hypertension 816 (14.9) 264373 (44.9) <0.001 
Dyslipidaemia 531 (9.7) 116967 (19.9) <0.001 
Type II diabetes mellitus 337 (6.2) 99030 (16.8) <0.001 
Heart failure 439 (8.0) 8416 (1.4) <0.001 
Atrial fibrillation and flutter 3267 (59.8) 33718 (5.7) <0.001 
Ischemic heart disease 171 (3.1) 15996 (2.7) 0.03 
Anaemia 351 (6.4) 31692 (5.4) <0.001 
Previous stroke 39 (0.7) 3919 (0.7) 0.36 
Stroke type 
Ischemic 
Haemorrhagic 
Undetermined 
 
3965 (72.6) 
703 (12.9) 
793 (14.5) 
 
302189 (51.3) 
194689 (33.0) 
92342 (15.7) 
 
 
 
<0.001 
*Characteristic data were compared between patients with and without mitral valve disease using chi squared 
analyses for categorical variables (gender, comorbidities, and stroke type) and independent samples t-test for 
continuous variables (age).  
†Age presented as mean (SD). All other data presented as n (%). 
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Table 2: Comparison of outcomes following stroke  
Outcome Mitral valve disease, n (%)  No mitral valve disease, n (%)  Pa 
N 5461  589220   
In-hospital mortality  566 (10.4) 69490 (11.8) 0.001 
Serious complications 
Respiratory failure 
Pneumonia 
Sepsis 
Acute MI 
Arrhythmias 
Cardiac arrest 
Shock 
 
527 (9.7) 
686 (12.6) 
225 (4.1) 
59 (1.1) 
44 (0.8) 
95 (1.7) 
84 (1.5) 
 
42001 (7.1) 
56060 (9.5) 
18926 (3.2) 
3356 (0.6) 
2541 (0.4) 
6117 (1.0) 
4436 (0.8) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Length of stay > 4 days  4 (5) 3 (4) <0.001 
MI – myocardial infarction.  Data are presented as median (IQR) for continuous data (length of stay) and 
number (%) for categorical data (in-hospital mortality, and complications). 
*Outcome data were compared between patients with and without mitral valve disease using chi squared 
analyses. 
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Table 3:  Association of mitral valve disease with development of complications following stroke (with no mitral valve disease as the reference 
category)    
Ischemic stroke, n=306,154 
Cardiovascular 
complications 
Model A* Model B† Model C‡ Model D‡ Model E‡ 
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Cardiac arrest 2.30 (1.82-2.90) <0.001 2.13 (1.68-2.70) <0.001 2.03 (1.60-2.58) <0.001 1.92 (1.51-2.44) <0.001 1.40 (1.09-1.79) 0.01 
Myocardial 
infarction 
 
1.52 (1.12-2.05) 
 
<0.001 
 
1.34 (0.99-1.83) 
 
0.06 
 
1.30 (0.95-1.77) 
 
0.1 
 
1.30 (0.95-1.76) 
 
0.1 
 
1.02 (0.75-1.40) 
 
0.89 
Shock 2.47 (1.92-3.19) <0.001 2.13 (1.64-2.77) <0.001 1.92 (1.48-2.50) <0.001 1.95 (1.50-2.53) <0.001 1.32 (1.01-1.72) 0.05 
Arrhythmias 1.58 (1.13-2.21) <0.001 1.70 (1.21-2.39) 0.003 1.65 (1.17-2.32) 0.004 1.65 (1.17-2.32) 0.004 1.15 (0.81-1.63) 0.43 
Respiratory 
Complications 
          
Respiratory failure 1.86 (1.67-2.07) <0.001 2.09 (1.87-2.33) <0.001 1.73 (1.53-1.94) <0.001 - - - - 
Pneumonia 1.55 (1.41-1.70) <0.001 2.00 (1.81-2.20) <0.001 - - - - - - 
Sepsis 1.27 (1.09-1.48) 0.003 1.39 (1.19-1.63) <0.001 - - - - - - 
Hemorrhagic stroke, n=195,392 
Complications Model A* Model B† Model C‡ Model D‡ Model E‡ 
Cardiovascular OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
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Cardiac arrest 1.29 (0.77-2.15) 0.33 1.19 (0.71-2.00) 0.50 1.22 (0.73-2.05) 0.45 1.16 (0.69-1.95) 0.57 0.87 (0.51-1.47) 0.59 
Myocardial 
infarction 
 
3.57 (1.90-6.69) 
 
<0.001 
 
1.87 (0.97-3.59) 
 
0.06 
 
1.88 (0.97-3.63) 
 
0.06 
 
1.88 (0.98-3.62) 
 
0.06 
 
1.21 (0.62-2.36) 
 
0.58 
Shock 1.80 (1.06-3.07) 0.03 1.45 (0.85-2.49) 0.18 1.32 (0.77-2.27) 0.31 1.42 (0.83-2.42) 0.20 0.91 (0.53-1.58) 0.74 
Arrhythmias 2.70 (1.12-6.54) 0.03 2.03 (0.83-4.99) 0.12 2.15 (0.87-5.28) 0.10 2.03 (0.83-4.98) 0.12 0.92 (0.37-2.30) 0.86 
Respiratory           
Respiratory failure 1.24 (1.01-1.53) 0.05 1.26 (1.01-1.57) 0.04 1.26 (1.01-1.57) 0.04 - - - - 
Infective           
Pneumonia 1.04 (0.83-1.30) 0.75 1.04 (0.83-1.30) 0.72 - - - - - - 
Sepsis 1.48 (1.06-20.6) 0.02 1.36 (0.98-1.91) 0.07 - - - - - - 
Undetermined, n=93,135     
Complications Model A* Model B† Model C‡ Model D‡ Model E‡ 
Cardiovascular OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
Cardiac arrest 1.76 (0.78-3.95) 0.17 1.67 (0.74-3.79) 0.23 1.61 (0.71-3.66) 0.25 1.61 (0.71-3.65) 0.26 1.29 (0.56-2.99) 0.55 
Myocardial 
infarction 
 
1.65 (0.68-4.01) 
 
0.27 
 
1.50 (0.61-3.70) 
 
0.38 
 
1.50 (0.61-3.69) 
 
0.38 
 
1.49 (0.60-3.66) 
 
0.39 
 
1.19 (0.48-2.97) 
 
0.71 
Shock 2.79 (1.38-5.65) 0.004 3.00 (1.46-6.14) 0.003 2.71 (1.32-5.55) 0.007 2.87 (1.40-5.87) 0.004 2.30 (1.09-4.83) 0.03 
Arrhythmias 1.40 (0.52-3.76) 0.50 1.43 (0.53-3.88) 0.48 1.43 (0.53-3.89) 0.48 1.40 (0.52-3.79) 0.51 0.92 (0.33-2.53) 0.87 
Respiratory           
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Respiratory failure 2.34 (0.68-3.26) <0.001 2.70 (1.91-3.79) <0.001 2.18 (1.53-3.11) <0.001 - - - - 
Infective           
Pneumonia 1.72 (1.35-2.20) <0.001 2.42 (1.88-3.11) <0.001 - - - - - - 
Sepsis 1.35 (0.84-2.16) 0.21 1.58 (0.99-2.55) 0.06 - - - - - - 
*Unadjusted. 
†Adjusted for age, gender, year of hospital admission, and previous history of major chronic disease (stroke, heart failure, chronic kidney disease, COPD, chronic ischemic 
heart disease, type II diabetes mellitus, and HIV).  
‡For cardiovascular complications, model C = model B with additional adjustment for primary hypertension; model D = model B with additional adjustment for 
dyslipidaemia; model E = model B with additional adjustment for atrial fibrillation and flutter.  
For the complication of respiratory failure, model C was additionally adjusted for post stroke pneumonia (no model D-E).  
For infective complications, there no additional covariate adjustments were made (no model C-E). 
‘Patients with no rheumatic mitral valve disease’ was the reference category and patient complications were dependent variables in regression models. 
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SUPPLEMENTAL MATERIAL 
Supplementary Table I: Propensity scoring results 
Ischemic stroke Adjusted using propensity 
scoring (n=7930) 
 
Complications OR (95% CI) P 
Cardiac arrest 2.08 (1.39-3.10) <0.001 
Myocardial infarction 1.47 (0.92-2.34) 0.10 
Shock 3.92 (2.26-6.80) <0.001 
Arrhythmias 1.03 (0.64-1.65) 0.90 
Respiratory failure 2.94 (2.41-3.59) <0.001 
Pneumonia 1.90 (1.50-2.41) <0.001 
Sepsis 1.46 (1.15-1.85) 0.002 
Hemorrhagic stroke OR (95% CI) P 
Cardiac arrest 1.51 (0.67-3.39) 0.32 
Myocardial infarction 0.91 (0.38-2.15) 0.83 
Shock 2.36 (0.90-6.18) 0.080 
Arrhythmias 1.67 (0.40-7.02) 0.48 
Respiratory failure 2.48 (1.72-3.58) <0.001 
Pneumonia 1.33 (0.83-2.14) 0.23 
Sepsis 2.55 (1.39-4.69) 0.003 
Undetermined stroke OR (95% CI) P 
Cardiac arrest 2.01 (0.50-8.06) 0.33 
Myocardial infarction 2.51 (0.49-12.97) 0.27 
Shock Not estimatable  
Arrhythmias 1 (0.25-4.01) 1.00 
Respiratory failure 5.50 (2.43-12.40) <0.001 
Pneumonia 3.03 (1.64-5.61) <0.001 
Sepsis 2.28 (0.99-5.27) 0.06 
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* Adjusted for age, gender, year of hospital admission, and previous history of major chronic disease (stroke, 
heart failure, chronic kidney disease, COPD, chronic ischemic heart disease, diabetes, HIV, primary 
hypertension, dyslipidaemia, and atrial fibrillation). 
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Supplementary Table II:  Multivariate regression analyses to examine factors associated with in-hospital mortality following stroke 
Ischemic stroke, n=306,154 Model A*  Model B† 
Covariates OR (95% CI) P Covariates OR (95% CI) P 
Rheumatic mitral valve disease 1.19 (1.06-1.34) <0.001 Age 1.01 (1.01-1.01) <0.001 
Age 1.02 (1.02-1.02) <0.001 Gender 1.28 (1.23-1.32) <0.001 
Gender 1.30 (1.26-1.34) <0.001 Previous stroke 3.81 (3.01-4.83) <0.001 
Previous stroke 4.18(3.41-5.12) <0.001 Heart failure 2.05 (1.90-2.22) <0.001 
Heart failure 3.76 (3.53-4.00) <0.001 Chronic kidney disease 1.15 (1.07-1.24) <0.001 
Chronic kidney disease 1.52 (1.43-1.62) <0.001 Chronic ischemic heart disease 1.49 (1.39-1.60) <0.001 
COPD 1.60 (1.48-1.62) <0.001 HIV 3.00 (2.28-3.97) <0.001 
Chronic ischemic heart disease 151 (1.42-1.61) <0.001 Type II diabetes mellitus 1.11 (1.07-1.16) <0.001 
HIV 2.89 (2.23-3.75) <0.001 Dyslipidaemia 0.45 (0.43-0.47) <0.001 
Type II diabetes 1.24 (1.19-1.28) <0.001 Myocardial infarction 4.21 (3.78-4.68) <0.001 
Hypertension 0.94 (0.91-0.97) <0.001 Shock 4.99 (4.47-5.56) <0.001 
Dyslipidaemia 0.40 (0.39-0.42) <0.001 Arrhythmias 1.84 (1.57-2.14) <0.001 
Alcohol  1.40 (1.23-1.60) <0.001 Respiratory failure 5.89 (5.65-6.13) <0.001 
   Pneumonia 3.12 (3.00-3.24) <0.001 
   Sepsis 8.18 (7.80-8.58) <0.001 
Hemorrhagic stroke, n=195,392 Model A*  Model B† 
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Covariates OR (95% CI) P Covariates OR (95% CI) P 
Age 1.01 (1.01-1.01) <0.001 Age 1.00 (1.00-1.01) <0.001 
Previous stroke 1.15 (1.06-1.25) <0.001 Previous stroke 1.10 (1.00-1.20) <0.001 
Heart failure 2.07 (1.87-2.29) <0.001 Heart failure 1.67 (1.50-1.86) <0.001 
Chronic kidney disease 1.40 (1.31-1.49) <0.001 Chronic kidney disease 1.23 (1.15-1.32) <0.001 
   Chronic ischaemic heart disease 1.29 (1.18-1.42) <0.001 
Chronic ischaemic heart disease 1.31 (1.20-1.43) <0.001 HIV 1.71 (1.29-2.28) <0.001 
HIV 1.80 (1.36-2.38) <0.001 Type II diabetes mellitus 1.09 (1.05-1.13) <0.001 
Type II diabetes mellitus 1.16 (1.12-1.21) <0.001 Hypertension 1.07 (1.04-1.09) <0.001 
Hypertension 1.09 (1.07-1.12) <0.001 Dyslipidaemia 0.37 (0.35-0.39) <0.001 
Dyslipidaemia 0.36 (0.34-0.37) <0.001 Myocardial infarction 2.65 (2.29-3.08) <0.001 
Alcohol 1.11 (1.04-1.19) <0.001 Shock 2.96 (2.71-3.24) <0.001 
   Arrhythmias 1.46 (1.20-1.76) <0.001 
   Respiratory failure 2.66 (2.59-2.74) <0.001 
   Pneumonia 1.05 (1.01-1.08) 0.007 
   Sepsis 3.88 (3.68-4.09) <0.001 
Undetermined, n=93,135 Model A*  Model B† 
Covariates OR (95% CI) P Covariates OR (95% CI) P 
Rheumatic mitral valve disease 1.67 (1.21-2.30) 0.001 Age 1.01 (1.01-1.01) <0.001 
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Age 1.02 (1.02-1.02) <0.001 Gender 1.15 (1.06-1.24) 0.002 
Gender 1.15 (1.07-1.24) 0.001 Heart failure 1.73 (1.39-2.16) <0.001 
Heart failure 2.48 (2.03--3.02) <0.001 Chronic kidney disease 1.36 (1.13-1.65) 0.001 
Chronic kidney disease 1.64 (1.38-1.95) <0.001 Chronic ischemic heart disease 1.33 (1.09-1.62) 0.005 
COPD 1.34 (1.08-1.65) 0.005 HIV 3.80 (1.57-9.18) 0.002 
   Dyslipidaemia 0.39 (0.34-0.46) <0.001 
Chronic ischemic heart disease 1.42 (1.18-1.70) 0.001 Alcohol 2.02 (1.46-2.78) <0.001 
HIV 4.19 (1.81-9.71) 0.001 Myocardial infarction 3.14 (2.25-4.39) <0.001 
Dyslipidaemia 0.39 (0.33-0.45) 0.001 Shock 3.85 (2.86-5.17) <0.001 
Alcohol 2.28 (1.68-3.08) 0.001 Arrhythmias 2.56 (1.74-3.76) <0.001 
   Respiratory failure 7.34 (6.50-8.29) <0.001 
   Pneumonia 3.15 (2.84-3.48) <0.001 
   Sepsis 8.43 (7.41-9.58) <0.001 
*Covariates were entered into this multivariate model using forward selection with a cut-off of 10% significance level from patient demographic and pre-existing comorbidity 
data (age, gender, and previous history of major chronic disease (stroke, heart failure, primary hypertension, dyslipidaemia, alcohol abuse, chronic kidney disease, COPD, 
chronic ischemic heart disease, type II diabetes, and HIV). 
†Additional post stroke complication data were entered into this model using forward selection with a cut-off of 10% significance level.
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